The CDC quietly announced last week that it was withdrawing its request to the FDA for Emergency Use Authorization (EUA) of the 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel, the assay first introduced in February 2020 for detection of SARS-CoV-2.
Most of the public is probably unaware that similar to the current COVID-19 injections that are not yet approved by the FDA, but only given Emergency Use Authorization, so too the hundreds of diagnostic tests that supposedly detect COVID-19 are also NOT approved by the FDA, but only authorized via an EUA.
What is the reason the CDC is withdrawing its EUA request for the Real-Time RT-PCR Diagnostic Panel?
In preparation for this change, CDC recommends clinical laboratories and testing sites that have been using the CDC 2019-nCoV RT-PCR assay select and begin their transition to another FDA-authorized COVID-19 test.
CDC encourages laboratories to consider adoption of a multiplexed method that can facilitate detection and differentiation of SARS-CoV-2 and influenza viruses. (Source.)
Caitlin McFall, writing for Fox News, is the only one in the corporate media I could find that even reported this, and the few reports I found in the Alternative media so far have been mostly inaccurate.
The Centers for Disease Control and Prevention (CDC) urged labs this week to stock clinics with kits that can test for both the coronavirus and the flu as the “influenza season” draws near.
The CDC said Wednesday it will withdrawal its request for the “Emergency Use Authorization” of real-time diagnostic testing kits, which were used starting in February 2020 to detect signs of the coronavirus, by the end of the year.
“CDC is providing this advance notice for clinical laboratories to have adequate time to select and implement one of the many FDA-authorized alternatives,” the agency said.
The U.S. has reported more than 34.4 million cases of the coronavirus since the pandemic began in 2020 and more than 610,000 deaths.
But while cases of COVID-19 soared nationwide, hospitalizations and deaths caused by influenza dropped.
According to data released by the CDC earlier this month, influenza mortality rates were significantly lower throughout 2020 than previous years.
There were 646 deaths relating to the flu among adults reported in 2020, whereas in 2019 the CDC estimated that between 24,000 and 62,000 people died from influenza-related illnesses.
The CDC urged laboratories to “save both time and resources” by introducing kits that can determine and distinguish a positive test for the coronavirus and flu. (Source.)
So there you have it. The CDC just basically admitted that many of the COVID-19 cases this past year could not be distinguished from “flu cases.” No wonder flu cases decreased to zero in so many places. See:
The ending of the EUA for the Real-Time RT-PCR Diagnostic Panel will not happen until the end of the year, December 31, 2021, and the CDC recommends that laboratories start transitioning to other types of COVID-19 diagnostic tests that have been given an EUA by the FDA here.
At the time of publication of this article, the FDA has issued 251 EUAs for COVID-19 diagnostic tests since April 1, 2020. The vast majority of them are for the RT-PCR tests, including about 20 that were just issued EUAs since the beginning of this month, July, 2021.
The cash cow for these tests and the hundreds of companies that got rich selling them will now have to move on to the next phase to be able to cash in.